Figure 3

Effect of ARG098 on infiltrating lymphocytes isolated from the synovium of RA patients and peripheral blood mononuclear cells (PBMCs) isolated from RA patients. (A) Representative infiltrating lymphocytes viability in the RA synovium following ARG098 treatment vs. the non-treated condition. Black circles, ARG098; white circles, human IgM. Each point represents mean ± SEM (n = 5). **: p < 0.01 vs. non-treated cells (Dunnett's test). (B) ARG098 binding activity to CD4⁺CD8^- T cells in lymphocytes isolated from RA patients was assessed by flow cytometory. The white area is stained with human IgM, and the black area is stained with ARG098. (C) ARG098 binding activity to CD4^-CD8⁺ T cells in lymphocytes isolated from RA patients. (D) Representative PBMC viability from the same RA patient following ARG098 treatment vs. the non-treated condition. Black circles, ARG098; white circles, human IgM. Each point represents mean ± SEM (n = 5). (E) ARG098 binding activity to CD4⁺CD8^- T cells in the PBMCs from RA patients. The white area is stained with human IgM and the black area is stained with ARG098. (F) ARG098 binding activity to CD4^-CD8⁺ T cells in the PBMCs from RA patients.